Tag: Pfizer
10 Highlights of the Year 2012 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2012, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community. Here are 10 of the year’s important stories:
1) NET Cancer Day, November …
READ MORE
Pancreatic Neuroendocrine Tumors: A Rare Cancer
From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States. This rare cancer is often…
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
CNETS Canada Presents 2011 Halifax Neuroendocrine Conference for Patients and Medical Professionals
Carcinoid and neuroendocrine tumor patients and medical professionals are invited to attend the 2011 Halifax Conference, presented by the Canadian Neuroendocrine Tumour Society (CNETS). The conference will be held on Saturday, May 7 at the beautiful…
READ MORE
Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting
Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …
READ MORE
